GoAI
Get started
Disc Medicine, Inc. logo

Disc Medicine, Inc.

IRON

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$79.69

+$0.97 · +1.23%

Aug 21, 3:55 PM ET

IRON company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

40

Expensive

Momentum

52

Neutral

Sentiment

50

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
John D. Quisel
Listed since
Aug 12, 2020
Employees
165

Market position

Volume
370.35K
0.74× average
Average volume
497.9K
Average daily volume
Market cap
3.06B USD
Beta
2.06
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-12.09×
P/B (TTM)
4.79×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.09×

Financial statements

Income trends

Operating income

−236.02M USD-81.95%

Net income

−212.18M USD-94.03%
Income trends across reported periods−10.42M USD−92.46M USD−174.5M USD−256.53M USDOperating income, FY2021: −30.93M USDOperating income, FY2022: −47.48M USDOperating income, FY2023: −91.13M USDOperating income, FY2024: −129.72M USDOperating income, FY2025: −236.02M USDNet income, FY2021: −35.97M USDNet income, FY2022: −46.83M USDNet income, FY2023: −76.43M USDNet income, FY2024: −109.36M USDNet income, FY2025: −212.18M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −30.93M USD. Operating income FY2022 −47.48M USD. Operating income FY2023 −91.13M USD. Operating income FY2024 −129.72M USD. Operating income FY2025 −236.02M USD. Net income FY2021 −35.97M USD. Net income FY2022 −46.83M USD. Net income FY2023 −76.43M USD. Net income FY2024 −109.36M USD. Net income FY2025 −212.18M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development170.64M USD96.67M USD69.26M USD33.44M USD25.17M USD
Selling, general, and administrative65.38M USD33.05M USD21.86M USD14.04M USD5.76M USD
Operating expenses236.02M USD129.72M USD91.13M USD47.48M USD30.93M USD
Interest income27.76M USD21.29M USD14.8M USD709K USD14K USD
Interest expense3.61M USD572K USD——2.16M USD
Depreciation and amortization281K USD156K USD100K USD89K USD32K USD
Operating income−236.02M USD−129.72M USD−91.13M USD−47.48M USD−30.93M USD
Net income−212.18M USD−109.36M USD−76.43M USD−46.83M USD−35.97M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$90.00

12.77% upside
Past 12 months12-month forecast

Price history unavailable

High $90.00Average $90.00Low $90.00

IRON news

newsfilecorp.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc.…

Read source
gurufocus.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire

Read source
prnewswire.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

NEW YORK, Aug. 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON)…

Read source
globenewswire.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON)…

Read source
globenewswire.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON)…

Read source
gurufocus.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire

Read source

IRON peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IRON

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
79.1M
Weight
0.69%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
75.21M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
57.42M
Weight
0.07%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
28.52M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
20.59M
Weight
0.14%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
16.28M
Weight
0.15%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
12.22M
Weight
0.07%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
12.16M
Weight
0.05%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research IRON

research.disclaimer